Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio Partners with Vanda for Imsidolimab Development
- AnaptysBio, Vanda announce exclusive global license agreement for Vanda
- Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
- AnaptysBio price target lowered to $36 from $66 at JPMorgan
- AnaptysBio price target lowered to $20 from $30 at Truist
Questions or Comments about the article? Write to editor@tipranks.com